News
A total of 1066 proposals were submitted in response to the MSCA Doctoral Networks 2023 call with proposal submission deadline on 28 November 2023. The number of proposals for each topic is shown below:
- Doctoral Networks (standard DN): 920 proposals (86.3% of total)
- Industrial Doctorates (DN-ID): 64 proposals (6.0% of total)
- Joint Doctorates (DN-JD): 82 proposals (7.7% of total)
Source: Funding and Tender Portal
More information on the number of coordinators per country that submitted a proposal and an indicative timeline of the evaluation process can be found in the European Commission MSCA news article
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
ESA Space Solutions has opened a call for proposals on space-enabled solutions for resilient electricity grids, in collaboration with ENTSO-E. The call supports proof-of-concept studies and pilot projects that address challenges in grid resilience and operational continuity.
Read moreThe Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.
Read moreThe launch of the 2027 calls for proposals under the Defence-related Research Action (DEFRA) programme has been postponed until Spring 2027. As a result, the information days initially scheduled for 23 and 24 November 2026 will also be postponed. A revised timeline will be communicated as soon as it becomes available.
Read moreThe European Partnership for Personalised Medicine (EP PerMed) is about to launch the joint transnational call 2027 (JTC2027) “Cell and Gene Therapy for Personalised Medicine”. The call opens on 4 November 2026.Proposals must focus on the development and validation of an innovative and novel cell and gene therapy for...
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
